Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Toripalimab + AG in Ampullary Carcinoma
NCT06062485Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of surufatinib in ampullary carcinoma, sponsored by Nanjing Drum-Tower Hospital. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
surufatinib
03
Conditions
ampullary carcinoma
Beyond the preview
Go deeper on NCT06062485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062485.